GKOS vs. BAX, SWAV, PODD, SOLV, TFX, GMED, PEN, MMSI, INSP, and HAE
Should you be buying Glaukos stock or one of its competitors? The main competitors of Glaukos include Baxter International (BAX), Shockwave Medical (SWAV), Insulet (PODD), Solventum (SOLV), Teleflex (TFX), Globus Medical (GMED), Penumbra (PEN), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP), and Haemonetics (HAE). These companies are all part of the "surgical & medical instruments" industry.
Glaukos (NYSE:GKOS) and Baxter International (NYSE:BAX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk, profitability and community ranking.
Glaukos has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.
Baxter International received 303 more outperform votes than Glaukos when rated by MarketBeat users. Likewise, 66.12% of users gave Baxter International an outperform vote while only 64.59% of users gave Glaukos an outperform vote.
Baxter International has a net margin of 17.79% compared to Glaukos' net margin of -43.15%. Baxter International's return on equity of 18.47% beat Glaukos' return on equity.
99.0% of Glaukos shares are owned by institutional investors. Comparatively, 90.2% of Baxter International shares are owned by institutional investors. 6.4% of Glaukos shares are owned by company insiders. Comparatively, 0.2% of Baxter International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Baxter International had 10 more articles in the media than Glaukos. MarketBeat recorded 16 mentions for Baxter International and 6 mentions for Glaukos. Glaukos' average media sentiment score of 0.61 beat Baxter International's score of 0.59 indicating that Glaukos is being referred to more favorably in the media.
Baxter International has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.
Glaukos currently has a consensus price target of $109.55, indicating a potential downside of 2.82%. Baxter International has a consensus price target of $44.42, indicating a potential upside of 30.29%. Given Baxter International's higher probable upside, analysts clearly believe Baxter International is more favorable than Glaukos.
Summary
Baxter International beats Glaukos on 11 of the 18 factors compared between the two stocks.
Get Glaukos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
